Patents by Inventor Ellen Garber

Ellen Garber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS
    Publication number: 20160185846
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Application
    Filed: June 22, 2015
    Publication date: June 30, 2016
    Applicant: BIOGEN MA INC.
    Inventors: Antonin R. DE FOUGEROLLES, Victor E. KOTELIANSKI, Carl REID, Ellen GARBER
  • Antibodies against monocyte chemotactic proteins
    Patent number: 9096665
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: August 4, 2015
    Assignee: Biogen MA Inc.
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber
  • ANTI-TIM-1 Antibodies And Uses Thereof
    Publication number: 20150110792
    Abstract: Antibodies and antibody fragments that bind to human TIM-1 on the BED face of the protein are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit or reduce TIM-1 binding to phosphatidylserine, inhibit or reduce TIM-1 binding to dendritic cells, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.
    Type: Application
    Filed: November 16, 2012
    Publication date: April 23, 2015
    Inventors: Veronique Bailly, Ellen Garber, Paul D. Rennert, Nicholas Joseph Lennemann, Wendy Jean Maury, Sven Henrik Moller-Tank
  • ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS
    Publication number: 20140178382
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Application
    Filed: April 16, 2013
    Publication date: June 26, 2014
    Applicant: Biogen IDEC MA, Inc.
    Inventors: ANTONIN R. DE FOUGEROLLES, VICTOR E. KOTELIANSKI, CARL REID, ELLEN GARBER
  • HUMANIZED ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS
    Publication number: 20140079697
    Abstract: The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.
    Type: Application
    Filed: July 2, 2013
    Publication date: March 20, 2014
    Applicant: Biogen Idec MA Inc.
    Inventors: Antonin R. DE FOUGEROLLES, Victor E. KOTELIANSKI, Ellen GARBER, Carl REID, Jose W. SALDANHA, Herman VAN VLIJMEN
  • Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
    Patent number: 8618252
    Abstract: The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: December 31, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Graham K. Farrington, Alexey Alexandrovich Lugovskoy, Werner Meier, John K. Eldredge, Ellen Garber
  • Humanized antibodies against monocyte chemotactic proteins
    Patent number: 8519112
    Abstract: The invention provides humanized antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: August 27, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Ellen Garber, Carl Reid, Jose W. Saldanha, Herman Van Vlijmen
  • Methods of treating lupus nephritis using antibodies against monocyte chemotactic proteins
    Patent number: 8431125
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: April 30, 2013
    Assignee: Biogen Idec MA, Inc.
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber
  • Nucleic acids encoding antibodies having altered effector function and methods for making the same
    Patent number: 8318917
    Abstract: The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: November 27, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Frederick R. Taylor, Ellen Garber
  • ANTIBODIES HAVING ALTERED EFFECTOR FUNCTION AND METHODS FOR MAKING THE SAME
    Publication number: 20120100575
    Abstract: The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.
    Type: Application
    Filed: December 21, 2010
    Publication date: April 26, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Frederick R. TAYLOR, Ellen GARBER
  • STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHODS OF USE
    Publication number: 20120100140
    Abstract: A method of producing Fc-containing polypeptides, such as antibodies, having stabilized Fc regions is provided, together with stabilized Fc polypeptides produced according to these methods as well as methods of using such antibodies as therapeutics.
    Type: Application
    Filed: January 22, 2010
    Publication date: April 26, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Christopher L. Reyes, Eric Chan, Frederick R. Taylor, Ellen Garber, Brian Robert Miller, Stephen Demarest, Scott Glaser
  • Anti-IGR-1R antibodies and uses thereof
    Patent number: 8147829
    Abstract: The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: April 3, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Kandasamy Hariharan, Scott Glaser, Ellen Garber, Christilyn Graff, Christopher L. Reyes, Stephen Demarest
  • ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS
    Publication number: 20120039873
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Application
    Filed: June 9, 2011
    Publication date: February 16, 2012
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber
  • TWEAK BINDING ANTIBODIES
    Publication number: 20120009178
    Abstract: Anti-Tweak antibodies are described.
    Type: Application
    Filed: September 9, 2011
    Publication date: January 12, 2012
    Inventors: Linda C. Burkly, Ellen Garber, Alexey Lugovskoy
  • NEONATAL Fc RECEPTOR (FcRn)- BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
    Publication number: 20120003210
    Abstract: The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.
    Type: Application
    Filed: December 13, 2010
    Publication date: January 5, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Graham K. FARRINGTON, Alexey Alexandrovich LUGOVSKOY, Werner MEIER, John K. ELDREDGE, Ellen GARBER
  • ANTI-LYMPHOTOXIN ANTIBODIES
    Publication number: 20120003235
    Abstract: The instant invention is based, at least in part on the identification of a new class of antibodies that result, e.g., in improved LT blocking capabilities. Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize LT?R signaling are also provided.
    Type: Application
    Filed: December 31, 2009
    Publication date: January 5, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Ann M. Ranger, Ellen Garber, Justin A. Caravella, Alexey A. Lugovskoy, Joseph Arndt, Frederick R. Taylor, Giovanna Antognetti, Eric Day
  • Tweak binding antibodies
    Patent number: 8048422
    Abstract: Anti-Tweak antibodies are described.
    Type: Grant
    Filed: November 26, 2007
    Date of Patent: November 1, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Linda C. Burkly, Ellen Garber, Alexey Lugovsky
  • SINGLE CHAIN Fc (ScFc) REGIONS, BINDING POLYPEPTIDES COMPRISING SAME, AND METHODS RELATED THERETO
    Publication number: 20110243966
    Abstract: The present invention features inter alia polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addition, the instant invention provides, e.g., methods for treating or preventing a disease or disorder in subject by administering the binding polypeptides of the invention to said subject.
    Type: Application
    Filed: March 14, 2011
    Publication date: October 6, 2011
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Graham K. FARRINGTON, Amna SAEED-KOTHE, Ellen GARBER, Alexey Alexandrovich LUGOVSKOY
  • HUMANIZED ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS
    Publication number: 20110236968
    Abstract: The invention provides humanized antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.
    Type: Application
    Filed: February 14, 2011
    Publication date: September 29, 2011
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Ellen Garber, Carl Reid, Jose W. Saldanha, Herman Van Vlijmen
  • Cripto binding molecules
    Patent number: 8021661
    Abstract: The invention pertains to humanized forms of an anti-CRIPTO antibody and portions thereof. In one embodiment, the variable regions of these antibodies or polypeptides comprising them (e.g., full-length antibodies or domain deleted antibodies) can be used to treat disorders, such as cancer.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: September 20, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Scott Glaser, Herman Van Vlijmen, Alexey Alexandrovich Lugovskoy, Michele Sanicola-Nadel, Xiufeng Wu, Ellen Garber, Jose William Saldanha